1. Introduction {#sec1}
===============

DNA methylation is one of the most commonly occurring epigenetic events in the mammalian genome. DNA methyltransferases (*DNMTs*) are critical to establishing and maintaining DNA methylation patterns by converting cytosine residues to 5-methylcytosine (5mC) in cytosine--guanine (CpG) dinucleotides \[[@B1], [@B2]\]. The DNMT family comprises three active forms: DNMT1, DNMT3A, and DNMT3B. DNMT1 is the major enzyme responsible for methylation maintenance \[[@B3], [@B4]\], while DNMT3A and DNMT3B are thought to function in de novo methylation rather than in methylation maintenance \[[@B3], [@B4]\].

*DNMT1* is located on human chromosome 19p13.2 and encodes a protein comprising 1632 amino acids, which may be implicated in occurrence progression and prognosis of the cancer. DNMT1 consists of three major structural elements: an N-terminal regulatory domain that is necessary for the localization of DNMT1; a C-terminal catalytic domain that is involved in the binding of substrates; and a central linker that contains repeated glycine-lysine dipeptides \[[@B5]\]. Genetic variation caused by single nucleotide polymorphisms (SNPs) is the most common form of altered gene structure. The most commonly studied*DNMT1* SNPs are rs16999593 (T/C), rs2228611 (G/A), and rs2228612 (A/G), which are present in coding regions and, therefore, may influence*DNMT1*expression.

In recent years, various studies have indicated that*DNMT1* polymorphisms may play pivotal roles in carcinogenesis. The SNPs rs16999593 (T/C) and rs2228612 (G/A) were initially found to be associated with risk of breast cancer \[[@B6], [@B7]\], while SNP rs2228611 (A/G) was linked to gastric cancer \[[@B8]\]. Subsequently, a number of studies have concentrated on the relationships between*DNMT1* polymorphisms and risks of different cancers \[[@B6], [@B7], [@B9]--[@B21]\]. However, the results from these studies are inconsistent.

Until now, no meta-analysis has been carried out to investigate the relation of the three*DNMT1* polymorphisms (rs16999593 (T/C), rs2228611 (G/A), and rs2228612 (A/G)) with risk of cancer. Individual studies have lacked the ability to obtain overall reliable conclusions because of limited sample sizes and/or variations in ethnicities. To obtain further insights into the roles of*DNMT1* polymorphisms in carcinogenesis, we mainly performed a meta-analysis on the associations between these three SNPs and cancer risk.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy {#sec2.1}
--------------------

We systematically searched the PubMed, Embase, Web of Science, and Chinese National Knowledge Infrastructure databases using different combinations of the search terms "*DNMT1* or DNA methyltransferase 1," "polymorphism or mutation or variant," and "cancer or neoplasm or tumor." The search was last updated on 06 June 2016. When overlapping data were found, only the largest and latest study was selected. We contacted the authors and requested their specific raw data when the data provided in the published article were not sufficient.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Studies were included when they met the following criteria: case-control study; the subject was the association of*DNMT1* polymorphisms (rs16999593 (T/C), rs2228611 (G/A), and rs2228612 (A/G)) with risk of cancer; and essential information on genotype or allele frequencies was available to assess the odds ratios (ORs) and 95% confidence intervals (CIs). Exclusion criteria included review articles; systematic reviews and meta-analyses; animal studies; sample size less than 100; and scarce or insufficient information on genotype or allele frequencies for the rs16999593 (T/C), rs2228611 (G/A), or rs2228612 (A/G) polymorphisms of*DNMT1* despite us contacting the authors.

2.3. Data Extraction {#sec2.3}
--------------------

Two of the authors (HL and JL) independently selected the articles and extracted the original data using a standardized and consistent method. The following information was collected from each study: first author, year of publication, ethnicity of the subjects, cancer type, numbers of cases and controls, and genotyping methods. Conflicts were resolved after discussion and consensus was finally reached on all the extracted information.

2.4. Statistical Analysis {#sec2.4}
-------------------------

All statistical analyses were conducted using STATA software (version 12.0; Stata Corp LP, College Station, TX). ORs and their corresponding 95% CIs were employed to assess the strength of relationships between the*DNMT1* polymorphisms and cancer risk. *P* values \< 0.05 were considered as statistically significant. Heterogeneity was calculated using the *Q* statistic (*P* value \< 0.10 indicates significant heterogeneity among studies) and *I*-squared value. The Mantel-Haenszel fixed-effects model was used to calculate the pooled ORs when the heterogeneity of studies was not significant. Otherwise, the DerSimonian and Laird random-effects model was used. We conducted the sensitivity analysis to explore heterogeneity when significant heterogeneity existed. Subgroup analysis was applied to explore the effects of cancer type and genotyping method. In addition, Begg\'s test and Egger\'s test were performed to evaluate publication bias; *P* values \< 0.05 for Begg\'s and Egger\'s tests indicate significant publication bias.

3. Results {#sec3}
==========

3.1. Characteristics of the Studies {#sec3.1}
-----------------------------------

This meta-analysis was organized according to the PRISMA (Supplementary File 1 in Supplementary Material available online at <https://doi.org/10.1155/2017/3971259>). A detailed flow chart of the study selection process is shown in [Figure 1](#fig1){ref-type="fig"}. A total of 215 potentially relevant articles were found by searching the four databases and after removing duplicates. Altogether 187 publications were excluded mainly due to no relevance, animal not human experiments, reviews, or meeting abstract. The 28 remaining articles were evaluated further for eligibility. Finally, 16 articles were included in the present meta-analysis \[[@B6]--[@B21]\].

The baseline characteristics of the 16 included studies are summarized in [Table 1](#tab1){ref-type="table"}. Among them, nine articles containing 3378 cases and 4244 controls surveyed the association between rs16999593 (T/C) and cancer risk \[[@B6], [@B7], [@B9]--[@B15]\]; 11 studies on the relation between rs2228611 (G/A) and cancer risk included 3643 cases and 3866 controls \[[@B6]--[@B8], [@B10], [@B11], [@B13], [@B14], [@B18]--[@B21]\]; and three publications containing 1343 cases and 1309 controls explored the correlation of rs2228612 (A/G) with cancer risk \[[@B7], [@B16], [@B17]\]. The populations surveyed in the nine rs16999593 (T/C) studies were all Chinese \[[@B6], [@B7], [@B9]--[@B15]\]. In the rs2228611 (G/A) studies, nine of the populations were Chinese \[[@B6], [@B7], [@B10], [@B11], [@B13], [@B14], [@B19]--[@B21]\], one was Iranian \[[@B8]\], and one was Polish \[[@B18]\]. In the rs2228612 (A/G) studies the populations were either Caucasian \[[@B16]\] or Chinese \[[@B7], [@B17]\]. The genotyping methods used to detect the*DNMT1* polymorphisms included sequencing, MassARRAY, PCR-RFLP, MALDI-TOF, TaqMan, and SNPlex \[[@B6]--[@B21]\]. We used subgroup analyses to explore the effects of different cancer types and genotyping methods on the associations of increased risk of cancer with the*DNMT1* rs16999593 (T/C) and rs2228611 (G/A) polymorphisms. We did not perform subgroup analysis for rs2228612 (A/G) because of the limited number of articles that was available.

3.2. Quantitative Data Synthesis {#sec3.2}
--------------------------------

The results for the association of*DNMT1* rs16999593 (T/C) with cancer risk are summarized in [Table 2](#tab2){ref-type="table"}. Overall, neither the heterozygous nor dominant genetic models found significant associations between rs16999593 (T/C) and cancer risk (TC versus TT: OR = 1.29, 95% CI = 0.90--1.84, *P* = 0.163; TC + CC versus TT: OR = 1.28, 95% CI = 0.93--1.77, *P* = 0.135). The allele analysis also found no significant association (C allele versus T allele: OR = 1.18, 95% CI = 0.96--1.45, *P* = 0.127). For the subgroup analysis according to cancer type ([Figure 2](#fig2){ref-type="fig"}), rs16999593 (T/C) was consistently associated with increased risk of gastric cancer (TC versus TT: OR = 1.36, 95% CI = 1.14--1.61, *P* = 0.001; TC + CC versus TT: OR = 1.36, 95% CI = 1.15--1.60, *P* \< 0.001; C allele versus T allele: OR = 1.28, 95% CI = 1.11--1.47, *P* = 0.001), but no significant association was found with breast cancer. For the different genotyping methods, rs16999593 (T/C) demonstrated increased risk of cancer in the sequencing subgroup but not in the MassARRAY subgroup.

The results for the association of*DNMT1* rs2228611 (G/A) with cancer risk are summarized in [Table 3](#tab3){ref-type="table"}. Overall, the GA genotype was not significantly associated with risk of cancer compared with the GG genotype (OR = 1.05, 95% CI = 0.92--1.21, *P* = 0.075), and the GA + AA genotype was not related to cancer risk compared with the GG genotype (OR = 1.05, 95% CI = 0.96--1.15, *P* = 0.284). Similarly, no significant association was observed in the allele analysis (A allele versus G allele: OR = 1.02, 95% CI = 0.95--1.10, *P* = 0.532). In the subgroup analysis according to cancer type ([Figure 3](#fig3){ref-type="fig"}), the rs2228611 (G/A) was associated with higher risk of breast cancer (GA versus GG: OR = 1.17, 95% CI = 1.03--1.33, *P* = 0.016; GA + AA versus GG: OR = 1.13, 95% CI = 1.00--1.28, *P* = 0.043). A similar result was found in the MALDI-TOF subgroup (GA versus GG: OR = 1.20, 95% CI = 1.03--1.41, *P* = 0.022) in the analysis according to different genotyping methods. For the gastric cancer and PCR-RFLP subgroups, no significant associations were found in any of the compared genetic models.

The results for the association of*DNMT1* rs2228612 (A/G) with cancer risk are summarized in [Table 4](#tab4){ref-type="table"} and [Figure 4](#fig4){ref-type="fig"}. Significant association with cancer risk was observed in the recessive model (GG versus AG + AA: OR = 1.29, 95% CI = 1.06--1.56, *P* = 0.009), but no significant association was revealed in the allele analysis (G allele versus A allele: OR = 1.00, 95% CI = 0.83--1.20, *P* = 0.980).

3.3. Heterogeneity Test and Sensitivity Analysis {#sec3.3}
------------------------------------------------

In most of the comparisons of DNMT1 rs16999593 and rs2228612 polymorphisms and one comparison of DNMT1 rs2228611, significant heterogeneity was observed. We next performed a leave-one-out sensitivity analysis. The results show that no individual study significantly affected the pooled OR (figure not shown), suggesting that the results of the meta-analysis were robust.

3.4. Publication Bias {#sec3.4}
---------------------

Begg\'s test and Egger\'s test were used to quantitatively evaluate the publication bias of the selected studies; the details are listed in [Table 5](#tab5){ref-type="table"}. For the associations of*DNMT1* rs16999593 (T/C), rs2228611 (G/A), and rs2228612 (A/G) with cancer risk, rs2228612 (A/G) showed publication bias (GG versus AA; G allele versus A allele) and rs16999593 (T/C) showed publication bias in the comparison with the recessive model.

4. Discussion {#sec4}
=============

DNMT1, the major methyltransferase in mammals, lies in the replication fork and methylates newly synthesized DNA strands directly in S phase of DNA replication sites \[[@B22]\], which is essential for epigenetic inheritance. Regional aberrant DNA hypermethylation has been identified as a possible mechanism of inactivation of tumor suppressor genes \[[@B23]\]. Many studies have indicated that the overexpression of*DNMT1* could silence vital tumor suppressor genes such as*APC*,*P16*, and*RUNX3* through DNA methylation \[[@B24], [@B25]\]. Therefore, DNMT1 might be implicated in the occurrence, development, and prognosis of multiple types of cancer.

Polymorphisms have been identified as a powerful tool for predicting hereditary susceptibility of some complex diseases including cancer. However, previous individual studies about the association between*DNMT1* polymorphisms and cancer risk were not only limited but also inconclusive. To our knowledge, this is the first comprehensive meta-analysis investigating the possible correlations of SNPs rs16999593 (T/C), rs2228611 (G/A), and rs2228612 (A/G) in*DNMT1* with risk of overall cancer and specific cancer types, which is anticipated to shed light on the role of*DNMT1* polymorphisms in carcinogenesis.

SNP rs2228612 (A/G) causes an isoleucine to phenylalanine substitution at amino acid 327 in the DNMT1 protein, which may alter the function of DNMT1 and influence its effect in the carcinogenesis. In this meta-analysis, we found that*DNMT1* rs2228612 (A/G) was associated with risk of overall cancer in the recessive model. However, only three articles with small-scale studies were available for analysis; therefore, the results should to be interpreted with caution.

We did not find significant association between SNP rs16999593 (T/C) and overall cancer risk in any genetic comparison. Different types of cancer have distinct initiation and progression mechanisms, in which polymorphisms in key genes play critical roles. This meta-analysis elucidated that the*DNMT1* rs16999593 (T/C) polymorphism was associated with different cancer types. In the subgroup analysis according to cancer type, the TC genotype of rs16999593 (T/C) was associated with risk of gastric cancer, but not breast cancer. Extensive evidence has suggested that DNA methylation is involved in the initiation and progression of gastric cancer and increased expression of*DNMT1* had been confirmed to be related to gastric cancer \[[@B25]\]. The AKT-NF*κ*B and STAT3 signaling pathways can upregulate*DNMT1* expression, which could cause aberrant DNA methylation of tumor suppressor genes and lead to gastric cancer \[[@B26], [@B27]\]. Therefore, SNP rs16999593 (T/C), which causes a histidine to arginine substitution at 97 positions of the amino acid sequence, might affect the function of DNMT1, thus increasing susceptibility to gastric cancer. The subgroup of breast cancer involved two types of breast cancer: sporadic triple-negative breast cancer (TNBC) \[[@B15]\] and infiltrating ductal beast carcinoma (IDBC) \[[@B6]\]. The TC genotype of rs16999593 (T/C) was related to increased TNBC risk but decreased IDBC risk. Therefore,*DNMT1* might have diverse functions in different types of breast cancer. Further studies of the effects of*DNMT1* polymorphisms on specific breast cancer types are still needed. In addition, only in the subgroup of sequencing,*DNMT1* rs16999593 (T/C) were constantly associated with increased cancer risk in all compared genetic models, indicating that different genotype detecting methods might influence the results.

According to the functional prediction tool F-SNP (<http://compbio.cs.queensu.ca/F-SNP/>), SNP rs2228611 (G/A) may change the regulation of*DNMT1* splicing by leading to a synonymous mutation at amino acid 463. Multiple transcript variants of DNMT1 gene as a result of alternative splicing have been found. Therefore, we speculated that the rs2228611 (G/A) might influence the process of carcinogenesis by regulating the pattern of alternative splicing of*DNMT1*. Here, we did not find any significant associations between*DNMT1* rs2228611 (G/A) with altered risk of cancer in any genetic model. However, in the subgroup analysis, individuals with the GA genotype of rs2228611 (G/A) were associated with higher risk of breast cancer in both heterozygous and dominant models. In addition, individuals with the GA genotype of rs2228611 (G/A) had decreased risk in one study on esophageal cancer \[[@B14]\], which was opposite to the results for breast cancer. This reverse outcome may be because various types of cancer have different mechanisms of carcinogenesis. Future studies on different types of cancer may help to better understand these findings.

Some limitations of our meta-analysis should be noted. Firstly, the number of studies was not sufficiently large, especially for subgroup analysis of*DNMT1* rs2228612 (A/G). Secondly, the languages of the publications were limited to English and Chinese. Thirdly, although this meta-analysis was based on the whole population, most studies were from Chinese populations, except for one Iranian case and one Polish case for rs2228611 (G/A) and another one Caucasian case for rs2228612 (A/G), which showed the same results with the Chinese population. So this study had a certain universality, especially for Chinese population. Finally, publication bias was found in two comparisons of rs2228612 (A/G) and one comparison of rs16999593 (T/C).

5. Conclusion {#sec5}
=============

The*DNMT1* rs2228612 (A/G) GG genotype may be associated with increased risk of cancer compared with the AA + AG genotype. SNP rs16999593 (T/C) is significantly associated with gastric cancer risk while SNP rs2228611 (G/A) is significantly related to breast cancer risk. Further large-scale and well-designed investigations including different cancers are required to verify the findings of this study.
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###### 

Characteristics of the included studies in this meta-analysis.

  Author                                    Year   Ethnicity   Cancer type            Genotyping method   Case   Control                                  
  ----------------------------------------- ------ ----------- ---------------------- ------------------- ------ --------- ----- ----- ------ ----- ----- -----
  *For DNMT1 rs16999593 T/C polymorphism*                                                                                                                 
  Wang \[[@B12]\]                           2014   Chinese     Cervical cancer        Sequencing          100    48        44    8     100    70    25    5
  Gao \[[@B13]\]                            2015   Chinese     Gastric cancer         Sequencing          310    180       112   18    420    281   117   22
  Li \[[@B14]\]                             2015   Chinese     Esophageal cancer      MassARRAY           258    138       80    40    260    127   109   24
  He et al. \[[@B11]\]                      2014   Chinese     Prostate cancer        MassARRAY           155    94        53    8     155    73    67    15
  Sun \[[@B7]\]                             2012   Chinese     Breast cancer          MassARRAY           1327   425       224   29    1440   504   202   28
  Xiang et al. \[[@B6]\]                    2010   Chinese     Breast cancer          PCR-RFLP            305    239       64    2     314    220   89    5
  Jiang et al. \[[@B9]\]                    2012   Chinese     Gastric cancer         Sequencing          447    283       144   20    961    659   273   29
  Yang et al. \[[@B10]\]                    2012   Chinese     Gastric cancer         MALDI-TOF           242    141       89    12    294    196   83    15
  Tao et al. \[[@B15]\]                     2015   Chinese     Breast cancer          Sequencing          234    68        164   2     300    180   105   15
  *For DNMT1 rs2228611 G/A polymorphism*                                                                                                                  
  Gao \[[@B13]\]                            2015   Chinese     Gastric cancer         Sequencing          310    167       128   15    420    232   163   25
  Li \[[@B14]\]                             2015   Chinese     Esophageal cancer      MassARRAY           258    131       85    42    260    119   113   28
  He et al. \[[@B11]\]                      2014   Chinese     Prostate cancer        MassARRAY           155    82        61    12    155    79    64    12
  Xiang et al. \[[@B6]\]                    2010   Chinese     Breast cancer          PCR--RFLP           305    125       149   31    314    154   121   39
  Yang et al. \[[@B21]\]                    2016   Chinese     Renal cell carcinoma   PCR--RFLP           293    152       117   24    293    139   133   21
  Yang et al. \[[@B10]\]                    2012   Chinese     Gastric cancer         MALDI-TOF           242    132       97    13    285    160   99    26
  Sun \[[@B7]\]                             2012   Chinese     Breast cancer          MassARRAY           678    341       279   58    733    369   303   61
  Mostowska et al. \[[@B18]\]               2013   Polish      Ovarian cancer         PCR--RFLP           159    28        74    57    210    44    94    72
  Xi et al. \[[@B19]\]                      2014   Chinese     Breast cancer          MALDI-TOF           810    385       362   63    848    432   343   73
  Lin et al. \[[@B20]\]                     2015   Chinese     Breast cancer          MALDI-TOF           233    107       109   17    236    120   94    22
  Khatami et al. \[[@B8]\]                  2009   Iranian     Gastric cancer         PCR--RFLP           200    34        50    16    112    32    62    18
  *For DNMT1 rs2228612 A/G polymorphism*                                                                                                                  
  Sun \[[@B7]\]                             2012   Chinese     Breast cancer          MassARRAY           675    254       273   148   731    308   290   133
  Chang et al. \[[@B17]\]                   2014   Chinese     Esophageal cancer      SNPlex              137    52        56    29    357    100   200   57
  Chang et al. \[[@B17]\]                   2014   Chinese     Stomach cancer         SNPlex              143    43        72    28    357    100   200   57
  Chang et al. \[[@B17]\]                   2014   Chinese     Liver cancer           SNPlex              158    48        74    36    357    100   200   57
  Kullmann et al. \[[@B16]\]                2013   Caucasian   Breast cancer          TaqMan              221    193       28    0     221    180   35    6

Abbreviations: W, wild-type allele; M, mutant-type allele.

###### 

Meta-analysis results of the association between *DNMT1* rs16999593 (T/C) polymorphism and cancer risk.

  Genetic model              Group/subgroup   *N*     Heterogeneity test   Statistical model   Test for overall effect                         
  -------------------------- ---------------- ------- -------------------- ------------------- --------------------------- ------------------- -------
  CC versus TT               Overall          9       37.5                 0.119               F                           1.17 (0.92--1.49)   0.213
  Gastric cancer             3                0.0     0.743                F                   1.36 (0.93--1.99)           0.117               
  Breast cancer              3                48.1    0.146                F                   0.93 (0.58--1.48)           0.748               
  Sequencing                 4                30.1    0.232                F                   1.33 (0.90--1.95)           0.149               
  MassARRAY                  3                66.1    0.052                R                   1.01 (0.53--1.93)           0.968               
                                                                                                                                               
  TC versus TT               Overall          9       89.70                \<0.001             R                           1.29 (0.90--1.84)   0.163
  Gastric cancer             3                00.00   0.540                F                   **1.36 (1.14**--**1.61)**   **0.001**           
  Breast cancer              3                95.90   \<0.001              R                   1.53 (0.62--3.80)           0.360               
  Sequencing                 4                90.30   \<0.001              R                   **2.06 (1.16**--**3.65)**   **0.013**           
  MassARRAY                  3                85.40   0.001                R                   0.84 (0.49--1.43)           0.517               
                                                                                                                                               
  (TC + CC) versus TT        Overall          9       88.60                \<0.001             R                           1.28 (0.93--1.72)   0.135
  Gastric cancer             3                00.00   0.720                F                   **1.36 (1.15**--**1.60)**   **\<0.001**         
  Breast cancer              3                95.50   \<0.001              R                   1.45 (0.62--3.40)           0.388               
  Sequencing                 4                88.40   \<0.001              R                   **1.99 (1.20**--**3.28)**   **0.007**           
  MassARRAY                  3                83.60   0.002                R                   0.88 (0.55--1.41)           0.603               
                                                                                                                                               
  CC versus (TC + TT)        Overall          9       48.7                 0.049               R                           1.03 (0.72--1.49)   0.861
  Gastric cancer             3                0.00    0.635                F                   1.22 (0.84--1.78)           0.303               
  Breast cancer              3                70.5    0.034                R                   0.49 (0.13--1.76)           0.274               
  Sequencing                 4                62.9    0.044                R                   1.00 (0.49--2.04)           0.998               
  MassARRAY                  3                65.8    0.054                R                   1.10 (0.59--2.05)           0.767               
                                                                                                                                               
  C allele versus T allele   Overall          9       81.40                \<0.001             R                           1.18 (0.95--1.45)   0.127
  Gastric cancer             3                00.00   0.936                F                   **1.28 (1.11**--**1.47)**   **0.001**           
  Breast cancer              3                91.50   \<0.001              R                   1.18 (0.71--1.97)           0.529               
  Sequencing                 4                66.30   0.030                R                   **1.53 (1.26**--**1.95)**   **\<0.001**         
  MassARRAY                  3                81.10   0.005                R                   0.96 (0.67--1.36)           0.805               

Abbreviations: R, random effect model; F, fixed effect model.

###### 

Meta-analysis results of the association between *DNMT1* rs2228611 (G/A) polymorphism and cancer risk.

  Genetic model              Group/subgroup   Studies   Heterogeneity test   Statistical model   Test for overall effect                         
  -------------------------- ---------------- --------- -------------------- ------------------- --------------------------- ------------------- -------
  AA versus GG               Overall          11        0.00                 0.925               F                           0.99 (0.84--1.19)   0.898
  Gastric cancer             3                0.00      0.774                F                   0.74 (0.49--1.13)           0.165               
  Breast cancer              4                0.00      0.979                F                   0.98 (0.78--1.22)           0.848               
  PCR--RFLP                  4                0.00      0.880                F                   1.04 (0.76--1.42)           0.803               
  MALDI-TOF                  3                0.00      0.511                F                   0.87 (0.65--1.17)           0.360               
                                                                                                                                                 
  GA versus GG               Overall          11        41.00                0.075               R                           1.05 (0.92--1.21)   0.445
  Gastric cancer             3                0.00      0.461                F                   1.07 (0.86--1.33)           0.522               
  Breast cancer              4                35.60     0.198                F                   **1.17 (1.03**--**1.33)**   **0.016**           
  PCR--RFLP                  4                64.00     0.040                R                   1.05 (0.73--1.52)           0.782               
  MALDI-TOF                  3                0.00      0.910                F                   **1.20 (1.03**--**1.41)**   **0.022**           
                                                                                                                                                 
  (GA + AA) versus GG        Overall          11        1.80                 0.425               F                           1.05 (0.96--1.15)   0.284
  Gastric cancer             3                0.00      0.618                F                   1.02 (0.83--1.26)           0.860               
  Breast cancer              4                1.50      0.385                F                   **1.13 (1.00**--**1.28)**   **0.043**           
  PCR--RFLP                  4                51.70     0.102                F                   1.06 (0.87--1.29)           0.542               
  MALDI-TOF                  3                0.00      0.872                F                   1.14 (0.98--1.33)           0.087               
                                                                                                                                                 
  AA versus (GA + GG)        Overall          11        0.00                 0.596               F                           0.97 (0.83--1.13)   0.671
  Gastric cancer             3                0.00      0.535                F                   0.76 (0.51--1.12)           0.169               
  Breast cancer              4                0.00      0.813                F                   0.90 (0.73--1.12)           0.351               
  PCR--RFLP                  4                0.00      0.779                F                   0.99 (0.76--1.29)           0.933               
  MALDI-TOF                  3                0.00      0.501                F                   0.80 (0.60--1.06)           0.126               
                                                                                                                                                 
  A allele versus G allele   Overall          11        0.00                 0.978               F                           1.02 (0.95--1.10)   0.532
  Gastric cancer             3                0.00      0.863                F                   0.96 (0.82--1.14)           0.660               
  Breast cancer              4                0.00      0.861                F                   1.06 (0.96--1.16)           0.249               
  PCR--RFLP                  4                0.00      0.530                F                   1.03 (0.90--1.18)           0.696               
  MALDI-TOF                  3                0.00      0.745                F                   1.04 (0.93--1.17)           0.494               

R: random effect model; F: fixed effect model.

###### 

Meta-analysis results of the association between *DNMT1* rs2228612 (A/G) polymorphism and cancer risk.

  Genetic model              Heterogeneity test   Statistical model   Test for overall effect                               
  -------------------------- -------------------- ------------------- ------------------------- --------------------------- -----------
  GG versus AA               19.20                0.292               F                         1.20 (0.97--1.49)           0.088
  AG versus AA               60.30                0.039               R                         0.81 (0.61--1.08)           0.156
  (GG + AG) versus AA        62.7                 0.030               R                         0.87 (0.66--1.14)           0.310
  GG versus (AA + AG)        11.50                0.340               F                         **1.29 (1.06**--**1.56)**   **0.009**
  G allele versus A allele   58.70                0.046               R                         1.00 (0.83--1.20)           0.980

R: random effect model; F: fixed effect model.

###### 

Results of publication bias test.

  Polymorphism               Compared genotype   Begg\'s test   Egger\'s test               
  -------------------------- ------------------- -------------- --------------- ----------- -----------
  *DNMT1* rs16999593 T/C     CC versus TT        0.94           0.348           −2.00       0.085
  TC versus TT               0.10                0.917          0.03            0.976       
  (TC + CC) versus TT        0.10                0.917          0.02            0.982       
  CC versus (TC + TT)        1.98                0.048          −2.72           **0.030**   
  C allele versus T allele   0.10                0.917          −0.45           0.669       
                                                                                            
  *DNMT1* rs2228611 G/A      AA versus GG        1.40           0.161           −0.99       0.348
  GA versus GG               0.78                0.436          −0.65           0.530       
  (GA + AA) versus GG        0.78                0.436          −0.69           0.505       
  AA versus (GA + GG)        0.47                0.640          −0.61           0.556       
  A allele versus G allele   0.93                0.350          1.17            0.273       
                                                                                            
  *DNMT1* rs2228612 (A/G)    GG versus AA        1.71           0.086           −3.97       **0.029**
  AG versus AA               0.24                0.806          −2.86           0.065       
  (GG + GA) versus AA        0.73                0.462          −3.81           **0.032**   
  GG versus (AA + AG)        0.73                0.462          −1.37           0.263       
  G allele versus A allele   2.20                **0.027**      −4.26           **0.024**   

[^1]: Academic Editor: Jinsong Ren
